Chinese biotech company HitGen Inc (688222.SH) said on Saturday that it has extended the previous drug discovery research collaboration to identify small molecule leads against targets specified by Morphic Therapeutic.
Pursuant to the extended agreement, HitGen will use its DNA-encoded library (DEL) technology platform based on the design, synthesis and interrogation and selection to discover ligands for targets of interest to Morphic.
In conjunction with the collaboration, Morphic will pay an assignment fee to HitGen in exchange for exclusive development and commercialization rights to compounds that achieve the criteria of the collaboration.
Additionally, HitGen's industry-leading DNA-encoded library (DEL) technology platform includes over 400bn encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients